This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
33
0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
Novo Nordisk Investigational Site
Graz, Austria
Area under the glucose infusion rate curve during one dosing interval at steady-date"
Time frame: After 8 days of treatment
Area under the serum Insulin Degludec concentration-time curve
Time frame: During one dosing interval at steady state
Area under the serum Insulin Degludec concentration-time curve
Time frame: From 0 to 24 hours after single dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.